| Bioactivity | PROTAC erf3a Degrader-2 (Compound C59) is an orally active PROTAC erf3a Degrader. PROTAC erf3a Degrader-2 inhibits protein expression of SRD5A3 and GSPT1(eRF3a). PROTAC erf3a Degrader-2 inhibits cancer cell proliferation (eg: 22Rv1). PROTAC erf3a Degrader-2 can be used for research of prostate cancer, ovarian cancer, liver cancer, cervical cancer, leukemia, breast cancer. (Red: erf3a ligand (HY-13778); Black: linker (HY-163960); Blue: E3 ligase ligand (HY-W763812))[1]. |
| CAS | 3033871-15-4 |
| Formula | C44H52N6O6 |
| Molar Mass | 760.92 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Guangliang Yu, et al. Medicine for treating human tumor by eRF3a targeting protein degradation mechanism. Patent. CN117801051A. |
PROTAC erf3a Degrader-2
CAS: 3033871-15-4 F: C44H52N6O6 W: 760.92
PROTAC erf3a Degrader-2 (Compound C59) is an orally active PROTAC erf3a Degrader. PROTAC erf3a Degrader-2 inhibits prote
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.